Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Regencell Bioscience Holdings Ltd (RGC)

Regencell Bioscience Holdings Ltd (RGC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Regencell Bioscience’s Standardized Formulae Are Shown to Reduce ADHD and ASD Symptoms in the Interim Results of its Second Efficacy Trial Business Wire - Mon Sep 12, 2022

Regencell Bioscience Holdings Limited (Nasdaq: RGC) (“ Regencell ”) today announced its interim results from its second efficacy trial.

RGC : 6.51 (-5.65%)
Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period Business Wire - Wed May 18, 2022

Regencell Bioscience Holdings Limited (NASDAQ: RGC):

RGC : 6.51 (-5.65%)
Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO Business Wire - Mon May 16, 2022

Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), an early-stage bioscience company focusing on the research, development and commercialization of Traditional...

RGC : 6.51 (-5.65%)
Regencell Describes Their Traditional Chinese Medicine ("TCM") Treatments and Recent Efficacy Trial Results in New Video Interview on SNN Network AccessWire - Tue Mar 1, 2022

LOS ANGELES, CA / ACCESSWIRE / March 1, 2022 / SNN Network, The Official Small-, Micro- and Nano-Cap News Source™, today published a new Video Interview with the team from Regencell Bioscience Holdings...

RGC : 6.51 (-5.65%)
Regencell Bioscience’s Investigational Liquid-Formula RGC-COV19TM Shows Effectiveness Through Its Enrolled Patients in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-day Treatment Period in its EARTH Efficacy Trial Business Wire - Wed Feb 16, 2022

Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“ Regencell ” or the “ Company ”) today announced the results from an analysis of a total of 37 individuals enrolled in its E valuation and...

RGC : 6.51 (-5.65%)
Regencell Bioscience Holdings Limited Appoints Dr. William Wing-Yan Lo, JP to its Board of Directors Business Wire - Mon Dec 13, 2021

Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), an early-stage bioscience company focuses on the research, development and commercialization of TCM for the treatment...

RGC : 6.51 (-5.65%)
Regencell Bioscience Holdings Limited Announces Over $1 Million Ordinary Share Purchase by CEO Business Wire - Mon Nov 22, 2021

Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), an early-stage bioscience company focuses on the research, development and commercialization of TCM for the treatment...

RGC : 6.51 (-5.65%)
Regencell Bioscience Holdings Limited Included in the MSCI World Micro Cap Index Business Wire - Mon Nov 22, 2021

Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), an early-stage bioscience company focuses on the research, development and commercialization of TCM for the treatment...

RGC : 6.51 (-5.65%)
Regencell Bioscience Holdings Limited Establishes a Joint Venture to Offer COVID Treatment Business Wire - Thu Sep 2, 2021

Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), today announced that Regencell Bioscience Limited (“Regencell HK”), the Company’s wholly-owned subsidiary...

RGC : 6.51 (-5.65%)
Regencell Bioscience Holdings Limited Announces Partial Exercise of Underwriter’s Over-Allotment Option Business Wire - Fri Aug 20, 2021

Regencell Bioscience Holdings Limited (NASDAQ:RGC) ("Regencell" or the "Company"), an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine...

RGC : 6.51 (-5.65%)

Barchart Exclusives

Dividend Aristocrats: The Best of the Best for Stable Income Barchart - 1 hour ago
Dividend Aristocrats' ability to increase their dividends indicates strong earnings and a solid business foundation, which lowers investment risk. Moreover, their consistent earnings growth often enables them to outperform broader market indices. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot